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Background: Mode of coronary revascularization in end stage renal disease (ESRD) patients remains a controversy due to lack of randomized 
clinical trials. Improvements in PCI technology including use of drug eluting stents has resulted in wide spread use of PCI in general population. We 
therefore conducted a meta-analysis comparing the mortality outcomes in ESRD patients undergoing PCI or CABG.
methods: A comprehensive time unlimited PubMed search revealed 19 studies comparing PCI and CABG in ESRD patients. Primary clinical 
endpoint was all-cause mortality at 30 days and 12 months follow-up. Long term mortality (24 and 36 months) was also calculated. Subgroup 
analyses were performed on patients undergoing PTCA vs. CABG and PCI vs. CABG. Odds ratio (OR) and confidence interval (CI) were estimated using 
random effects model.
results: Of the 32696 patients analyzed 17385 underwent PCI and 15311 underwent CABG. Revascularization with PCI was associated with 
decreased mortality at 30 days in both PTCA and PCI groups compared to CABG. However, this mortality benefit was not maintained at subsequent 
follow-up (24, 36 months) with CABG being superior among all groups. In a sensitivity analysis excluding the 2 largest studies (n=30090), CABG 
remained associated with lower mortality at long term follow-up (Table).
conclusion: In ESRD patients undergoing coronary revascularization with PCI, short-term mortality was low however, at longer-term follow-up; CABG 
was associated with a lower risk of all-cause death. 
All-Cause Mortality in ESRD Patients Undergoing PCI or CABG
Follow-up PTCA CABG OR (95% CI)
30 days 397/7456 (5.3%) 976/8072 (12.1%) 0.48 (0.30-0.77)
12 months 2286/7374 (31%) 2304/7994 (28.8%) 1.28 (0.96-1.71)
24 months 3430/7319 (46.9%) 3325/7932 (41.9%) 1.65 (1.11-2.45)
36 months 4111/7166 (57.4%) 4299/7770 (55.3%) 1.52 (0.94-2.45)
PCI with stent CABG OR (95% CI)
30 days 26/515 (5.0%) 27/299 (9.03%) 0.38 (0.21-0.68)
12 months 25/126 (19.8%) 17/111 (15.3%) 1.58 (0.63-3.99)
24 months 43/126 (34.1%) 22/111 (19.8%) 1.93 (1.00-3.70)
36 months 64/160 (40%) 36/115 (31.3%) 1.40 (0.47-4.14)
PCI with stent+PTCA CABG OR (95% CI)
30 days 934/17304 (5.4%) 1596/15247 (10.5%) 0.56 (0.42-0.76)
12 months 5422/16844 (32.2%) 4273/14990 (28.5%) 1.22 (1.01-1.46)
24 months 8255/16778 (49.2%) 6302/14919 (42.2%) 1.51 (1.29-1.77)
36 months 4240/7473 (56.7%) 4385/8038 (54.6%) 1.49 (1.05-2.10)
PTCA= percutaneous transluminal angioplasty; CABG= coronary artery bypass grafting; PCI = percutaneous coronary intervention; OR = odds 
ratio; CI = confidence interval
